JCRB1032 OZ

細胞情報

Important Notice(s)

On the agreement for distribution of JHH series cell lines, NOZ and OZ

細胞種類:一般細胞 (細胞分譲手数料はこちら)

細胞番号(JCRB)   JCRB1032 細胞名   OZ
生物種(日本語)   ヒト 組織名(日本語)   肝臓, 胆嚢
コメント(日本語)   胆管がん プロフィール   Human bile duct cell line established from ascites of the tumor patient who had differentiated adenocarcinoma.
別名    動物名   human
系統名    学名・属名   Homo
種名   sapiens 性別   M
年齢・月齢   71 細胞識別情報   available
(癌)原発組織名   liver, gallbladder 病歴情報   differentiated adenocarcinoma papilla and poorly differentiated adenocarcinoma. CEA 8.0 ng/ml.
転移の有無(Y/N)   Yes (癌)転移組織名   ascites
遺伝的性質   No. of chromosome, 51. Td=48 hrs. 細胞寿命   infinite
クライシスPDL    形態   epithelial-like
一般性状   Cells were established from ascites of the patient whose bile duct was emphraxed by mucinous materials produced by adenocarcinoma cells. Cells produce CEA, BMG. High levels of P1-P, r-GTP, LDH were observed in cells. PAS (+). Transplantalbe to nude mice. 細胞分類   tumor
細胞樹立者名   Honma,S. & Nagamori,S. 細胞寄託者   Nagamori,S.
分譲時制限   Require negotiation and agreement from Dr.Nagamori before shipping. コメント   Cell Bank will handle to get the approval but the depositor may contact to the requested person directly. (r-GPT = gamma GPT)
入手年   2001 培養培地   Williams'E medium with 10% fetal calf serum.
継代方法   Cells are harvested after treatment with 0.25% trypsin and 0.02% EDTA. 継代時細胞数   
人種   Japanese 炭酸ガス濃度   5 %
採取組織名   ascites ウィルス検査   tested
検出ウィルス   GAPDH(+), CMV(-), EBV(-), HHV6(-), HHV7(-), BKV(-), JCV(-), ADV(-), HBV(-), parvoB19(-), HTLV1(-), HTLV2(-), HIV1(-), HIV2(-), HPV18(-)[-/negative, +/positive, nt/not tested,GAPDH is positive control] 組織型   
Reference
Pubmed id:2889643 Human bile duct carcinoma cell line producing abundant mucin in vitro.
Homma S,Nagamori S,Fujise K,Yamazaki K,Hasumura S,Sujino H,Matsuura T,Shimizu K,Kameda H,Takaki K
Gastroenterol Jpn. 1987 Aug;22(4):474-9


Research results by users. Click!
Pubmed id:22639408 Twisted gastrulation expression in cholangiocellular and hepatocellular carcinoma.
Johnston J,Al-Bahrani R,Abuetabh Y,Chiu B,Forsman CL,Nagamori S,Leng R,Petryk A,Sergi C
J Clin Pathol. 2012 Oct;65(10):945-8
Pubmed id:23084587 Overexpression of epithelial-mesenchymal transition-related markers according to cell dedifferentiation: clinical implications as an independent predictor of poor prognosis in cholangiocarcinoma.
Ryu HS,Chung JH,Lee K,Shin E,Jing J,Choe G,Kim H,Xu X,Lee HE,Kim DG,Lee H,Jang JJ
Hum Pathol. 2012 Dec;43(12):2360-70
Pubmed id:22457476 Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
Moldenhauer G,Salnikov AV,Lüttgau S,Herr I,Anderl J,Faulstich H
J Natl Cancer Inst. 2012 Apr 18;104(8):622-34
Pubmed id:22309595 Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma.
Miura S,Mitsuhashi N,Shimizu H,Kimura F,Yoshidome H,Otsuka M,Kato A,Shida T,Okamura D,Miyazaki M
BMC Cancer. 2012 Feb 6;12():56
Pubmed id:22075503 Expression of E-cadherin and β-catenin in two cholangiocarcinoma cell lines (OZ and HuCCT1) with different degree of invasiveness of the primary tumor.
Abuetabh Y,Persad S,Nagamori S,Huggins J,Al-Bahrani R,Sergi C
Ann Clin Lab Sci. 2011 Summer;41(3):217-23
Pubmed id:20922056 Mesothelin as a potential therapeutic target in human cholangiocarcinoma.
Yu L,Feng M,Kim H,Phung Y,Kleiner DE,Gores GJ,Qian M,Wang XW,Ho M
J Cancer. 2010 Oct 1;1():141-9
Pubmed id:20565817 Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.
Xu L,Hausmann M,Dietmaier W,Kellermeier S,Pesch T,Stieber-Gunckel M,Lippert E,Klebl F,Rogler G
BMC Cancer. 2010 Jun 18;10():302
Pubmed id:20044606 Infrequent amplification of JUN in hepatocellular carcinoma.
Endo M,Yasui K,Nakajima T,Gen Y,Tsuji K,Dohi O,Zen K,Mitsuyoshi H,Minami M,Itoh Y,Taniwaki M,Tanaka S,Arii S,Okanoue T,Yoshikawa T
Anticancer Res. 2009 Dec;29(12):4989-94
Pubmed id:19319137 Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma.
Yoshikawa D,Ojima H,Kokubu A,Ochiya T,Kasai S,Hirohashi S,Shibata T
Br J Cancer. 2009 Apr 21;100(8):1257-66
Pubmed id:19453019 Rapamycin inhibits growth of cholangiocarcinoma cells.
Okada T,Sawada T,Kubota K
Hepatogastroenterology. 2009 Jan-Feb;56(89):6-10
Pubmed id:18442209 Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines.
Xu LN,Wang X,Zou SQ
World J Gastroenterol. 2008 Apr 28;14(16):2578-81
Pubmed id:19383345 Exon 2 deletion splice variant of gamma-glutamyl carboxylase causes des-gamma-carboxy prothrombin production in hepatocellular carcinoma cell lines.
Ueda N,Shiraha H,Fujikawa T,Takaoka N,Nakanishi Y,Suzuki M,Matsuo N,Tanaka S,Nishina S,Uemura M,Takaki A,Shiratori Y,Yamamoto K
Mol Oncol. 2008 Oct;2(3):241-9
Pubmed id:15492814 Anti-endostatin monoclonal antibody enhances growth of human hepatocellular carcinoma cells by inhibiting activity of endostatin secreted by the transplanted cells in nude mice.
Tsuboi S,Nouso K,Tomono Y,Nagamori S,Naito I,Watanabe T,Manabe K,Ohmori H,Nakatsukasa H,Miyazaki M,Higashi T,Shiratori Y,Namba M,Ninomiya Y
Int J Oncol. 2004 Nov;25(5):1267-71
Pubmed id:12654561 Development of a therapeutic adenoviral vector for cholangiocarcinoma combining tumor-restricted gene expression and infectivity enhancement.
Nagi P,Vickers SM,Davydova J,Adachi Y,Takayama K,Barker S,Krasnykh V,Curiel DT,Yamamoto M
J Gastrointest Surg. 2003 Mar-Apr;7(3):364-71
Pubmed id:9446792 Cyclin E overexpression responsible for growth of human hepatic tumors with p21WAF1/CIP1/SDI1.
Tsuji T,Miyazaki M,Fushimi K,Mihara K,Inoue Y,Ohashi R,Ohtsubo M,Hamazaki K,Furusako S,Namba M
Biochem Biophys Res Commun. 1998 Jan 14;242(2):317-21
Pubmed id:9135018 Tamoxifen-mediated growth inhibition of human cholangiocarcinoma.
Sampson LK,Vickers SM,Ying W,Phillips JO
Cancer Res. 1997 May 1;57(9):1743-9
Pubmed id:8835345 Persistence of hepatitis C virus RNA in established human hepatocellular carcinoma cell lines.
Tsuboi S,Nagamori S,Miyazaki M,Mihara K,Fukaya K,Teruya K,Kosaka T,Tsuji T,Namba M
J Med Virol. 1996 Feb;48(2):133-40
Pubmed id:1701409 Integration of hepatitis B virus DNA into cells of six established human hepatocellular carcinoma cell lines.
Fujise K,Nagamori S,Hasumura S,Homma S,Sujino H,Matsuura T,Shimizu K,Niiya M,Kameda H,Fujita K
Hepatogastroenterology. 1990 Oct;37(5):457-60
Pubmed id:2889643 Human bile duct carcinoma cell line producing abundant mucin in vitro.
Homma S,Nagamori S,Fujise K,Yamazaki K,Hasumura S,Sujino H,Matsuura T,Shimizu K,Kameda H,Takaki K
Gastroenterol Jpn. 1987 Aug;22(4):474-9
Pubmed id:3005723 [Effects of hyperthermia on the proliferation and viability of cultured human hepatobiliary carcinoma cells].
Homma S,Nagamori S,Fujise K,Sujino H,Matsuura T,Simizu K,Kameda H
Nihon Shokakibyo Gakkai Zasshi. 1985 Sep;82(9):2043-8
Pubmed id:none 高分化型ヒト不死化肝細胞株(OUMS‐29)と肝癌細胞株(JHH‐1)でのエンドスタチン分泌の相違
友野靖子 安藤香織 内藤一郎 佐渡義一 坪井壮 永森静志 宮崎正博 沖垣達 二宮善文
重井医学年報 24, 7-14 (2003)
Pubmed id:none 樹立ヒト肝癌株細胞中のB型肝炎ウイルスゲノム
藤瀬 清隆, 藤多 和信, 永森 静志, 蓮村 哲, 本間 定, 筋野 甫, 松浦 知和, 清水 恵一郎, 新谷 稔, 大野 典也, 亀田 治男
肝臓 29(5), 697-698 (1988)
Pubmed id:none ヒト肝胆道系癌培養細胞の生存と増殖に及ぼす温熱の効果
本間 定, 永森 静志, 藤瀬 清隆, 筋野 甫, 松浦 知和, 清水 恵一郎, 亀田 治男
肝臓 24(5), 569 (1983)

Images
Movies



LOT Information

細胞番号   JCRB1032 細胞名   
培養ロット番号   05222012 培養種別   distribution
培地   Williams' E medium with 10% fetal bovine serum (FBS, GIBCO Cat. # 10099) 培養温度   37 C
継代時細胞数(濃度)   1 - 3 x 10^5 cells/mL 継代方法   Cells were harvested after treatment with 0.25% trypsin and 0.02% EDTA.
増殖速度   3 - 4 days 凍結時生細胞濃度   2.0 x 10^6
凍結直後生細胞率   93.0 使用抗生物質   free
継代数   Unknown (16 at bank) PDL数(プライマリ)   
マイコプラズマ検出   - 細菌汚染検出   -
真菌汚染検出   - アイソザイム検査・動物名   Confirmed as human by NP, G6PD (type B), MD.
染色体モード    染色体情報   
表面抗原    DNA Profile (STR)   
接着性   Yes 導入外部遺伝子   
凍結培地   10% DMSO, 20% FBS - Williams' E 炭酸ガス濃度   5%
RFPL所見    追加情報   
細胞番号   JCRB1032 細胞名   
培養ロット番号   03192007 培養種別   distribution
培地   William's E medium with 10% fetal bovine serum (FBS lot; GIBCO 484375) 培養温度   37 C
継代時細胞数(濃度)   approx. 1 x 10^5 cells/ml 継代方法   0.25% trypsin and 0.02% EDTA, passage once a week. Cells attached hard to dishes and trypsinization at 37 C for 20-30 minutes required.
増殖速度   80 hrs 凍結時生細胞濃度   1.8 x 10^6
凍結直後生細胞率   98.3 使用抗生物質   free
継代数   Unknown (9 at bank) PDL数(プライマリ)   
マイコプラズマ検出   - 細菌汚染検出   -
真菌汚染検出   - アイソザイム検査・動物名   Confirmed as human by NP and G6PD, LD, MD.
染色体モード    染色体情報   
表面抗原    DNA Profile (STR)   
接着性   Yes 導入外部遺伝子   
凍結培地   10% DMSO, 20% FBS - William's E medium 炭酸ガス濃度   5%
RFPL所見    追加情報   
細胞番号   JCRB1032 細胞名   OZ
培養ロット番号   02212003 培養種別   distribution
培地   Williams'E medium with 10% fetal calf serum(Intergen RB52305). 培養温度   37 C
継代時細胞数(濃度)   1.2 x 10^4 cells/sq.cm. 継代方法   Cells were harvested after treatment with 0.2% trypsin. Medium change twice a week and subculture every 10 days..
増殖速度   NT 凍結時生細胞濃度   1.4 x 10^6
凍結直後生細胞率   96.1 使用抗生物質   free
継代数   P6* PDL数(プライマリ)   NT
マイコプラズマ検出   - 細菌汚染検出   -
真菌汚染検出   - アイソザイム検査・動物名   G6PD(not shown), NP, LDH examined. Human.
染色体モード   NT 染色体情報   NT
表面抗原   NT DNA Profile (STR)   
接着性   Yes 導入外部遺伝子   NT
凍結培地   Culture medium with 5% DMSO. 炭酸ガス濃度   5 %
RFPL所見   NT 追加情報   
Images
CLOSE